Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2020-12-15 Director's Dealing
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2020-12-15 English
Regulatory Filings 2020
Regulatory Filings
2020-12-07 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 4, 2020, by Mustang Bio, Inc. It reports an amendment to the company's Certificate of Incorporation to increase authorized shares. The content focuses on corporate governance changes related to capital structure, specifically an increase in authorized common stock shares. There are no financial statements or detailed financial performance data included, nor is it an earnings release or annual/interim report. The primary subject is a capital structure change, which aligns with the Capital/Financing Update category. The document length is 4390 characters, which is relatively short but contains substantive information about the amendment rather than just announcing a report publication. Therefore, the best classification is Capital/Financing Update (CAP).
2020-12-04 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details an offering of common stock up to $100 million, describing the terms of the offering, the sales agreement with agents, risk factors, use of proceeds, dividend policy, and other related information. This type of document is a capital raising disclosure related to financing activities. It is not an annual or quarterly report, audit report, earnings release, or any other type of report. It is specifically a prospectus supplement related to a securities offering, which falls under Capital/Financing Update filings. Therefore, the correct classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is not merely an announcement but the actual offering document.
2020-12-04 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a letter to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references the Securities Act of 1933 and Rule 461, which relate to registration statements for securities offerings. The document is short (1728 characters) and is a formal correspondence about the filing status, not a financial report or detailed disclosure. It does not contain financial data, management discussion, or audit information. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory communication about a filing status rather than the filing itself or a report.
2020-12-02 English
DEF 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'DEF 14C' and is described as an 'Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934.' It details a stockholder action by written consent to approve an amendment to the company's certificate of incorporation to increase authorized shares. The document includes voting results, ownership information, and legal background on the action taken. DEF 14C filings are typically information statements provided to shareholders regarding corporate actions that do not require a proxy solicitation. This is not a proxy solicitation (which would be DEF 14A), nor is it a voting results announcement (DVA). It is an information statement related to shareholder action by written consent. According to the filing definitions, this fits best under Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or actions. The document is substantive and not a brief announcement or certification, so it is not RNS or RPA. Therefore, the correct classification is PSI with high confidence.
2020-11-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.